CDC Group Finds No Evidence to Support Use of LabCorp's ColoSure Test in General Risk Population
March 23, 2011
CDC Group Finds No Evidence to Support Use of LabCorp's ColoSure Test in General Risk Population
Exact Sciences, which licensed the intellectual property behind ColoSure to LabCorp, is developing a next-generation, multi-gene test for colorectal cancer and plans to start clinical trials later this year to support a premarket approval application with the FDA.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Data from Exact Sciences' Clinical Trial Sends Stock Plunging
April 18, 2013 / GenomeWeb Daily News - Exact Sciences Posts Flat Q2 Revenues
July 25, 2012 / GenomeWeb Daily News - Exact Sciences on Path to Filing PMA for Cologuard in 2012
July 13, 2011 / Pharmacogenomics Reporter - UPDATE: Exact Sciences' Q1 Revenues Drop 23 Percent
May 3, 2011 / GenomeWeb Daily News - AHRQ's Clancy Discusses Comparative Effectiveness Research/Personalized Medicine Convergence at PMC Conference
November 4, 2009 / Pharmacogenomics Reporter